The Food and Drug Administration approved a first-in-class precision therapy for metastatic pancreatic cancer on Aug. 26, offering new hope for patients with one of the deadliest forms of the disease.
Pancreatic cancer carries one of the lowest five-year survival rates of any cancer, historically under 12%, and kills more than 50,000 Americans annually, according to the FDA. Patients with metastatic disease have had extremely limited treatment options.
The approval is characterized as a targeted therapy, meaning the drug attacks a specific molecular pathway in cancer cells rather than killing rapidly dividing cells broadly as traditional chemotherapy does, the FDA said. The targeted approach is designed to improve effectiveness while reducing side effects.
The approval represents a potential breakthrough for a disease that has seen fewer advances than many other cancers. While precision medicine has transformed treatment for breast cancer, lung cancer, and melanoma, pancreatic cancer has largely resisted similar progress.
For the estimated 64,000 Americans diagnosed with pancreatic cancer each year, the approval opens a new treatment avenue. Oncologists have long sought targeted options for the disease, which is frequently diagnosed at advanced stages when surgery is no longer an option.
The approval is part of a remarkable week of FDA activity that also included first-in-class approvals for dermatomyositis and polycythemia vera, signaling accelerated progress in drug development for diseases with historically limited therapeutic options.
The drug’s manufacturer, pricing, and specific molecular target were detailed in the FDA’s full approval announcement.